<DOC>
	<DOC>NCT00363870</DOC>
	<brief_summary>The purpose of this study is to demonstrate the efficacy of GSK Biologicals' influenza vaccine (Fluarixâ„¢) administered intramuscularly in adults.</brief_summary>
	<brief_title>A Study to Demonstrate the Efficacy of GSK Biologicals' Influenza Vaccine in Adults</brief_title>
	<detailed_description />
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A male or female age between 18 and 64 years at the time of the first vaccination. nonchildbearing female Use of nonregistered products Pregnancy Hypersensitivity to a previous dose of influenza vaccine Acute disease at the time of enrolment/vaccination. History of allergy or reactions likely to be exacerbated by any component of the vaccine Administration of any other influenza vaccine for the season 20062007 Chronic disorders of the pulmonary or cardiovascular system, including asthma. Administration of immunemodifying drugs Administration of immunoglobulins and/or any blood products History of requiring regular medical followup or hospitalization during the preceding year because of chronic metabolic diseases (including diabetes mellitus), renal dysfunction, hemoglobinopathies, asthma or immunosuppression (including immunosuppression caused by medications or by human immunodeficiency virus)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Influenza vaccine</keyword>
	<keyword>Prophylaxis Influenza vaccine</keyword>
</DOC>